One Size Does Not Fit All: Using Population Pharmacokinetics (PK) for Tailored Hemophilia Care

One Size Does Not Fit All: Using Population Pharmacokinetics (PK) for Tailored Hemophilia Care is organized by CME Outfitters, LLC.

Premiere Date: Tuesday, March 03, 2020
Credit Expiration Date: Wednesday, March 3, 2021

This activity offers CE credit for:
• Physicians (CME)
• Nurses (CNE)
• Pharmacists (ACPE)
• ABIM (MOC)
• Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, assigns this Online CME session for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians can claim the credit commensurate based on the extent of their participation in the session.

CNE Credit (Nurses):
The provider is authorized by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-20-002-L01-P
Enduring: 0376-0000-20-002-H01-P

ABIM MOC Credit:
Successful completion of this CME activity involves participation in the evaluation component that permits an attendee to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Respondents will gain MOC points commensurate to the amount of CME credits claimed for the session. It is the responsibility of a CME activity provider's to present a participant completion information to ACCME for the intention of awarding ABIM MOC credit.

Statement of Need:
In order to prevent and treat bleeding in patients with hemophilia A, the activity of the replaced clotting factor VIII must reach or exceed a target level over a period of time. Pharmacokinetic (PK) measures are therefore used to determine the dosing regiment of different factor VIII replacement products. Recently, extended half-life recombinant factor VIII products with improved PK profiles have been approved and these reduce treatment burden and improve treatment adherence.

In this CME Outfitters live and on-demand webcast, renowned hematologists will discuss the clinical significance of the results of the head-to-head comparison study of PK profiles of extended half-life factor VIII products including the application of population PK models and shared decision-making to provide personalized hemophilia A therapy.

Learning Objectives:
At the conclusion of this CE activity, attendees should be able to:
• Summarize the comparative PK data and the clinical significance of popPK studies on factor VIII replacement therapies.
• Apply popPK models to determine individualized dosing regiments for patients with hemophilia A.
• Integrate approaches for SDM to develop patient-centered, PK-based treatment plans for patients with hemophilia A.

The following learning objectives pertain only to those requesting CNE or CPE credit:
• Summarize the comparative PK data and the clinical significance of popPK studies on factor VIII replacement therapies.
• Explain popPK models that can determine individualized dosing regimens for patients with hemophilia A.
• Describe approaches for SDM to develop patient-centered, PK-based treatment plans for patients with hemophilia A.